UnitedHealth Beats Q1 Estimates, But Stock Edges Down 0.28% After Hours

UnitedHealth Group topped Wall Street’s Q1 revenue and profit forecasts, but the market shrugged — shares slipped 0.28% in after-hours trading. The standout: a better-than-expected medical loss ratio of 82.4%.

UnitedHealth Q1 earnings beat, stock dips after hours
UnitedHealth beat Q1 estimates, but the market had already priced in the good news, sending shares down 0.28% after hours.

UnitedHealth Group (UNH) beat Wall Street’s Q1 2026 revenue and profit estimates, but the market barely reacted — shares edged down 0.28% in after-hours trading as of 5:30 PM ET on July 2.

  • Revenue: $100.8B, up 12% YoY, above the $99.5B consensus.
  • Adjusted EPS: $7.24, topping the $7.10 estimate.
  • Medical Loss Ratio (MLR): 82.4%, better than the 82.8% expected — a sign of tighter cost control.
  • Operating cash flow: ~$8.5B, up 15% YoY.
  • FY 2026 adjusted EPS guidance: unchanged at $29.50–$30.00.

UnitedHealth Group (NYSE: UNH) reported its Q1 2026 results after the bell on July 2. Revenue and profit both came in ahead of analyst estimates, but the stock barely budged in extended trading. As of 5:30 PM ET, UNH traded at $425.36, down 0.28% (-$1.18) from the close of $426.54. During the regular session, the stock opened at $428.13, hit a high of $430.20, and dipped to $420.54.[Yahoo Finance]

Revenue and Profit Beat Estimates, Medical Cost Control Shines

UnitedHealth’s Q1 total revenue hit $100.8B, up 12% year-over-year and above the $99.5B consensus. Adjusted EPS came in at $7.24, also ahead of the $7.10 analyst estimate.[Modern Healthcare]

The Medical Loss Ratio — the share of premiums spent on medical claims — was 82.4%, below the 82.8% the Street had penciled in. A lower MLR generally signals better cost control, and this print suggests UnitedHealth managed medical expenses more effectively than expected.[Reuters]

Strong Operating Cash Flow, Full-Year Guidance Unchanged

Operating cash flow came in at roughly $8.5B for the quarter, up 15% from a year ago — a sign of robust cash generation from the core business. The company reaffirmed its full-year 2026 adjusted EPS guidance of $29.50 to $30.00.[Modern Healthcare]

CEO Andrew Witty said on the earnings call that the company made progress expanding healthcare coverage and improving operational efficiency, particularly in the Optum health services segment, which posted strong revenue growth. But he cautioned that medical cost inflation remains a headwind, and UnitedHealth will continue to manage costs through technology investments and process improvements.[Reuters]

Market Shrugs, Stock Edges Down After Hours

Despite the beat, UnitedHealth shares slipped just 0.28% in after-hours trading. Analysts suggested the market had already priced in much of the good news. The decision to hold full-year guidance steady — rather than raising it — may have also been seen as a lack of upside surprise.[Yahoo Finance]

Notably, UnitedHealth wasn’t among the worst performers in the S&P 500 during the first half of 2026. According to MarketWatch, the 20 biggest decliners in the index were concentrated in software and online services — Intuit (INTU) fell 61%, CoStar Group (CSGP) dropped 58% — while healthcare held up relatively well.[MarketWatch]

Regulatory and Investment Developments

On the business development front, UnitedHealth recently announced a $385,000 investment in Nebraska to support local healthcare and workforce development — part of a longer-term strategy to expand its primary care network and address labor shortages.[Yahoo Finance]

Meanwhile, a new bill in Congress would require tax-exempt hospitals to disclose more financial information. If passed, it could affect pricing and reimbursement negotiations between insurers like UnitedHealth and hospitals.[Modern Healthcare]

This content is for informational purposes only and does not constitute investment advice, trading advice, or any guarantee of returns.

Keep Reading

US House Probes Merck, AbbVie China Trials; Eli Lilly, Pfizer, BMS Also Questioned

US House Probes Merck, AbbVie China Trials; Eli Lilly, Pfizer, BMS Also Questioned

The House Select Committee on China this week sent letters to several major drugmakers demanding details on the ethical and security risks of their Chinese clinical trials, reigniting fears of a US-China biotech decoupling. As of after-hours trading on July 2, Eli Lilly (LLY) closed at $1,208.39, up 1.40% from the prior close.

  • Committee Chairman John Moolenaar sent letters to Merck, AbbVie, and others, demanding responses by July 17.
  • The letters ask whether trials involved sites linked to the People's Liberation Army
Read full story →

Stay ahead of the market — never miss a deep dive

Follow OurAlpha for AI-driven US equity research and market insight, every day.